Lights and shadows of molecular pathology and immunotherapy in adjuvant setting of patients with pancreatic ductal adenocarcinoma: Tumor volume and microsatellite instability inversely affect early progression free survival

Objectives Molecular alterations in about 1% of Pancreatic Ductal AdenoCarcinoma(PDAC) includes MicroSatellite Instability (MSI) and damage of DNA Mismatch Repair (MMR) system. Immunotherapy (IT) with ICK inhibitors constitutes a source of personalized treatment for MSI cancer patients and support the evaluation of MSI phenotype in PDAC. The aim of this study is to evaluate MSI in metastatic PDAC patients after surgery featuring first line of chemotherapy (CT) in order to evaluate a possible immunotherapy treatment.

Source: Pancreatology - June 1, 2018 Category: Gastroenterology Authors: Niccola Funel, Luca Emanuele Pollina, Matteo Palmeri, Gregorio Di Franco, Simone Guadagni, Niccol ò Furbetta, Desirée Gianardi, Matteo Bianchini, Manuel Gentiluomo, Daniele Campa, Enrico Vasile, Lorenzo Fornaro, Silvia Catanese, Giulio Di Candio, Alfred Tags: 4. Experimental pancreatitis and cell biology II Source Type: research